# Pizarra — PT-pseudo_0de7e606ca70 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0de7e606ca70
Task: 1

Encounter: Urology - outpatient on 15 Jan 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 9.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.409 ng/mL²
  - PSA velocity: 1.24 ng/mL/yr
  - Prior PSA: 7.8 ng/mL
  - Prostate volume: 22.03 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.886139 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: valsartan, lisinopril
  - Allergies: NKA
  - Additional notes: PSA 9 ng/mL. PI-RADS 5. PSAD 0.41. Prostate volume 22 mL. csPCa 0.89.

Vitals: weight 76 kg, height 183 cm, BMI 22.7, BP 138/91 mmHg, HR 78 bpm. Smoking: Ex-smoker (27 pack-yr, quit 2017).

Chief complaint: Clinical attention directed toward steadily climbing PSA values alongside newly acquired mpMRI results.

History: Primary care surveillance has tracked his PSA trajectory for approximately two years. He is a sixty-five-year-old retired truck driver, never married, yet residing with his partner. Daily habits feature a twenty-minute walking regimen and a weekly alcohol intake capped at four units. Chronic hypertension remains stable on valsartan and lisinopril. He also carries a smoking background of 27 pack-years, though cessation occurred in 2017. Lower urinary tract complaints are minimal, scoring a 7 on the IPSS questionnaire, and he has never experienced urinary retention or visible blood in the urine. Outside of urological care, he recently completed a standard hearing evaluation and consulted a pain specialist regarding persistent right shoulder aches. Administrative correspondence and paperwork are handled by his grown daughter, acting with explicit permission.

Physical examination: DRE: A normal prostate presents with symmetrically smooth contours and uniform consistency, devoid of discrete masses or lateral asymmetry. Systemic evaluation shows stable vitals: a blood pressure of 138/91 mmHg and a pulse rate of 78 bpm. Comprehensive review of systems and vital parameters indicates no peripheral adenopathy or skeletal tenderness.

Patient info: retired truck driver; Never married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 4 units / week; exercise Walking 20 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Pain clinic — chronic shoulder pain.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.92 +/- 0.03   (95% CI 0.86-0.99)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.03  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.39 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI report provide sufficient detail on the lesion size and comparison to prior studies to confirm the PI-RADS 5 finding?
  - psa_trend (get_psa_trend) -> Does the PSA history show a significant rate of change that warrants immediate intervention?
  - previous_notes (get_previous_notes) -> What was the prior management plan and what was agreed upon with the patient regarding surveillance?

This case hinges on integrating the high-risk PI-RADS 5 finding with the patient's clinical context and serial PSA trend to confirm the expert protocol recommendation. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (9.0 ng/mL), PI-RADS 5, PSA density (0.409 ng/mL²), and prior biopsy status (None). It cannot weigh the context provided by the retrieved documents, such as the PSA velocity (1.24 ng/mL/yr), the clinical context (e.g., DRE findings being Normal), or the specific details from the mpMRI prose or PSA history trend.

WHY THE SUGGESTION COULD BE WRONG
The prior suggests a high probability of biopsy (0.92), but this could be wrong because the model did not account for the potential conflict between the high-risk PI-RADS 5 finding and the normal DRE, or the rising PSA velocity (1.24 ng/mL/yr). The high aleatoric uncertainty (H=0.39) suggests the data itself is highly mixed, meaning the model cannot resolve whether the PI-RADS 5 finding is truly indicative of clinically significant cancer given the other features.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI report provide sufficient detail on the lesion size and comparison to prior studies to confirm the PI-RADS 5 finding?
psa_trend - Does the PSA history show a significant rate of change that warrants immediate intervention?
previous_notes - What was the prior management plan and what was agreed upon with the patient regarding surveillance?
previous_notes - What was the prior management plan and what was agreed upon with the patient regarding surveillance?
previous_notes - What was the prior management plan and what was agreed upon with the patient regarding surveillance?
GUIDELINE ANCHOR
Guidelines suggest biopsy when the mpMRI shows a PI-RADS 3 or higher lesion, and the track record supports this criterion in biopsy-naive patients.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion located in the right peripheral zone, maximum diameter near 14 mm. Contrast kinetics show prompt, pronounced focal uptake.
get_psa_trend
PSA trend: Aug 2023: 3.3 ng/mL, Feb 2024: 4.6 ng/mL, Jul 2024: 6.4 ng/mL, Jan 2025: 9.0 ng/mL.
get_previous_notes
Previous notes: On 20 May 2024, PSA was 7.6 ng/mL, prompting transfer to urology for specialized evaluation and further imaging. No prior biopsy result is documented.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents did not raise a specific question requiring this panel (e.g., regarding free-PSA or renal function before an invasive procedure).

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion located in the right peripheral zone with a maximum diameter near 14 mm.
- PSA trend: Significant rate of change, with PSA rising from 3.3 ng/mL (Aug 2023) to 9.0 ng/mL (Jan 2025).
- Previous notes: The patient was referred to urology due to a consistent climb in PSA, indicating a need for specialized evaluation.

AGAINST sampling this patient now:
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The combination of a high-risk PI-RADS 5 finding and a rapidly rising PSA trajectory strongly supports the expert protocol recommendation for biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 5 lesion, significant PSA trend, and prior referral context) strongly supports the EXPERT-PROTOCOL recommendation for biopsy.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The EXPERT-PROTOCOL criterion mandates biopsy for a PI-RADS 5 lesion, which was confirmed by the retrieved MRI report. This was further strengthened by the significant PSA trend, rising from 3.3 ng/mL to 9.0 ng/mL over two years. The statistical prior also strongly suggested biopsy, and the retrieved evidence confirmed the protocol recommendation.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
